Three Nature Papers. A 200% Lifespan Claim. Zero Published Survival Curves. Inside the First Trial to Rejuvenate Aging Immune Cells.
SenTcell, a UCL spinout founded by immunologist Alessio Lanna, will begin the first-in-human trial of immune cell rejuvenation later this year. While senolytics kill senescent cells, SenTcell's intramuscular injection reprograms exhausted T cells to regain youthful function. Lanna's published work spans three papers in Nature journals establishing the molecular mechanism. His unpublished claim that treated rodents lived to "the equivalent of 120 human years" implies a 160–200% lifespan extension, which would be the largest ever reported for a single intervention. No survival curves supporting the lifespan claims have been published. An original audit of the senolytic clinical trial landscape reveals that fewer than 150 people have ever received systemic senolytics in published studies, and the leading drug combination actually increased epigenetic aging markers in a Phase I pilot.
One hundred and thirty-one. That is every human being who has ever swallowed a systemic senolytic drug in a published clinical trial, the entire evidence base for a field backed by more than $2 billion in longevity-sector investment, ten studies spread across a decade, and fewer participants than you'd find in a mid-sized corporate yoga class on a Tuesday morning. Now a UCL spinout called SenTcell is preparing to test something nobody has tried in humans: instead of killing aging immune cells, rejuvenating them.
SenTcell announced on June 17 that it received support through the UK's Medicines and Healthcare products Regulatory Agency (MHRA) Innovative Licensing and Access Pathway for a Phase 1 trial expected to begin later in 2026. Participants will receive an intramuscular injection designed to reprogram exhausted CD4+ T cells, the so-called "conductors" of the immune system that coordinate responses to infection, cancer, and chronic disease, with initial enrollment focusing on adults living with HIV who experience accelerated immune aging despite effective antiretroviral therapy.
Kill or Cure: Two Philosophies, One Problem
Senolytics and immune rejuvenation attack the same biological enemy from opposite directions. As senescent cells accumulate with age, they secrete a cocktail of inflammatory molecules collectively known as the senescence-associated secretory phenotype (SASP), and the senolytic bet is to eliminate these cells entirely before they poison their neighbors. SenTcell's approach is the inverse: reverse the dysfunction, restore senescent T cells to a younger functional state, keep them alive and working.
Both strategies have scientific logic, but only one has peer-reviewed mechanistic evidence spanning three papers in Nature journals while only the other has any human clinical data at all, and neither, it turns out, has both.
SenTcell's scientific foundation rests on two decades of work by founder Alessio Lanna and collaborators at UCL, beginning with a 2014 discovery that the kinase p38, activated through an unconventional intracellular pathway involving AMPK and the scaffold protein TAB1, drives senescence in human T cells (Nature Immunology, 15, 965–972). Block p38 and T cell function returns. Three years later, Lanna's team discovered that sestrins coordinate a simultaneous Erk-Jnk-p38 MAPK activation complex called sMAC that accumulates preferentially in T cells from people over 65 and, critically, that disrupting this complex enhanced vaccine responsiveness in old mice (Nature Immunology, 18, 354–363).
What came next was the strangest finding of the entire research program. A 2022 paper in Nature Cell Biology showed that antigen-presenting cells (APCs) can donate their telomeres to T cells through extracellular vesicles at the immunological synapse (24, 1461–1474), with the trimming factor TZAP cleaving telomeres from the donor cell's chromosomes and the recombination factor RAD51 fusing them to the recipient T cell's chromosome ends, adding roughly 3,000 base pairs per transfer event. Remarkable detail: this process worked even in TERT-knockout T cells, bypassing telomerase entirely. Rejuvenated T cells showed reinforced long-term immunological memory against influenza in mice, and Lanna has since proposed that these telomere-carrying vesicles, which he calls "telomere rivers," might explain how rejuvenated immune cells influence tissue health throughout the body far beyond the immune compartment itself.
Auditing the 200% Claim
In press interviews accompanying the trial announcement, Lanna stated that "in animal trials this kind of rejuvenation increased the life of a rodent by four to five years" and that treated animals "lived to the equivalent of 120 human years." Run the arithmetic against known benchmarks. Standard C57BL/6 laboratory mice have a median lifespan of approximately 30 months. Adding four to five years of additional life would produce a total lifespan of 6.5 to 7.5 years, representing an extension of 160 to 200% above baseline, which, if true, would constitute the largest mammalian lifespan extension ever reported for any single intervention by a factor of roughly four: the current published record is approximately 50%, achieved in Ames dwarf mice through growth hormone receptor disruption, with caloric restriction reaching 30 to 40% and transient rapamycin managing 60% in one optimistic study.
Not a single one of the three published Nature papers contains survival curve data. No cohort sizes for any lifespan experiment have been disclosed, no statistical methodology has been described, no strain information beyond the word "rodent" has been shared, and no age-at-treatment has been reported. The animal data may well exist internally at SenTcell and simply await peer review. But the gap between published mechanistic work and headline-grabbing lifespan figures is precisely the kind of discrepancy that aging researchers, burned by decades of mouse-to-human translation failures, have learned to interrogate before celebrating.
What the Senolytic Scoreboard Actually Shows
Meanwhile, the senolytic field's own human data is thinner than most people realize. A comprehensive Nature Aging analysis published in February 2026 tested 21 reported senolytic drugs head-to-head and found that only two compounds, ABT263 (navitoclax) and ARV825, demonstrated robust senolytic activity, while dasatinib plus quercetin (D+Q), the combination underlying nearly every human senolytic trial ever run, was not among the top performers.
Count the published clinical evidence: 14 patients with idiopathic pulmonary fibrosis in an open-label pilot, nine with diabetic kidney disease under the same uncontrolled design, twelve in a randomized IPF trial that found no differences between treatment and placebo groups, five Alzheimer's patients in a feasibility study barely large enough to generate a confidence interval, sixty postmenopausal women in the field's only properly powered RCT (which failed its primary endpoint of reducing bone resorption but showed a modest increase in bone formation markers), twelve more Alzheimer's-risk patients with no control group, and finally 19 people in a DNA methylation study that produced the most alarming result of all: six months of D+Q treatment increased epigenetic age acceleration and decreased telomere length. Fisetin partially attenuated the epigenetic damage when added to the cocktail, but still: the leading senolytic combination made its subjects biologically older by the very clocks the field uses to measure success.
Unity Biotechnology, the first company to take senolytics to clinical scale, trades at $0.06 per share after its lead candidate UBX0101 failed a 183-patient osteoarthritis trial, and while more than 20 additional senolytic trials remain registered on ClinicalTrials.gov, the evidentiary gap between animal promise and human proof remains vast for both camps.
What This Doesn't Prove
SenTcell's Phase 1 trial will enroll adults with immune dysfunction, not healthy elderly volunteers, and its primary endpoints are safety and biological activity rather than lifespan extension, healthspan improvement, or disease prevention. Even if the treatment safely rejuvenates T cells in HIV patients, that result cannot be extrapolated to aging in the general population, because HIV-associated immune senescence involves chronic viral antigen stimulation and, while it shares molecular features with age-related T cell exhaustion including elevated p38 MAPK signaling and telomere shortening, the two processes diverge in etiology and are not interchangeable.
Mouse-to-human translation in aging research has a brutal track record. Caloric restriction produced dramatic rodent lifespan extensions but showed no survival benefit in the NIA's 25-year rhesus macaque study, yielding only modest metabolic improvements in primates that lived no longer than their well-fed peers. Rapamycin reliably extends mouse lifespan but causes immunosuppression, glucose intolerance, and wound healing delays in clinical use. No intervention that has extended rodent lifespan by even 30% has demonstrated equivalent human lifespan extension. Claiming 200% based on unpublished rodent data from a company whose founder stands to benefit financially is exactly the kind of signal that demands independent replication, published survival curves, and peer review before anyone breaks out the champagne.
Additionally, the published telomere transfer mechanism was demonstrated only in specific T cell subsets under controlled in vitro conditions, and whether a single intramuscular injection can reliably trigger this process systemically across the heterogeneous, aging, inflammation-laden immune system of a living human being remains entirely unknown.
The Bottom Line
Two competing visions of anti-aging medicine are crystallizing: senolytics, which want to take out the garbage, and immune rejuvenation, which wants to repair what is broken rather than discard it. After a decade of work on both sides, neither camp has clinical proof in humans that its approach extends healthspan, but SenTcell's mechanistic foundation is among the most rigorous in the longevity space, with three high-impact papers demonstrating exactly how T cells age and exactly how they might be reversed. A positive Phase 1 result would validate an entirely new therapeutic category.
What you can do: If you are over 50, your most evidence-backed immune maintenance strategies remain stubbornly prosaic: consistent exercise (which preserves thymic output and naive T cell production), adequate sleep, and staying current on vaccinations, all of which cost less than a single dose of quercetin and have actual randomized trial data behind them. No commercially available senolytic supplement, including fisetin and quercetin sold over the counter, has demonstrated clinical benefit in a controlled human study. For those in the UK with HIV or chronic immune dysfunction, SenTcell's Phase 1 trial may open enrollment later this year; watch for the ClinicalTrials.gov registration, which will specify eligibility criteria and study sites. For everyone else: the published science is genuinely exciting. Published survival curves would be more so.
Related
- The First Company to Bet on Killing Zombie Cells Is Worth $0.06. Thirty Trials Still Think It's a $53 Billion Idea.
- Seven Anti-Aging Drugs Entered Clinical Trials. The Two That Worked Weren't Tested on Humans.
- An FDA-Approved Drug Cut Biological Age by 22% in 12 Weeks. It Wasn't Designed to Do That.